利古斯特拉纳米颗粒抑制了表皮-介质细胞过渡,并缓解了手术后的腹部粘附
Shasha Liang1, Yifei Qian2, Ying Liu3
1Teaching and Research Office of Obstetrics and Gynecology, Medical College of Zhengzhou University of Industrial Technology, Xinzheng, 451100, Henan, China.
Biochemical and biophysical research communications
|November 15, 2024
概括
利古斯特拉纳米颗粒 (LN) 通过减少炎症和上皮-介质细胞过渡 (EMT) 在大鼠中有效减少术后腹部粘附 (PAA). 在等待进一步的临床研究的情况下,LN显示了PAA治疗的潜力.
科学领域:
- 生物医学工程 生物医学工程
- 手术并发症研究研究
- 纳米医学是一种纳米医学.
背景情况:
- 手术后腹部粘附 (PAA) 是腹部手术后的一个常见并发症.
- 在PAA中Ligustrazine纳米颗粒 (LN) 的分子机制,特别是它们在表皮-介质细胞过渡 (EMT) 中的作用,尚未完全理解.
研究的目的:
- 研究利古斯特拉纳米颗粒 (LN) 对术后腹部粘附 (PAA) 的治疗作用和分子机制.
- 在PAA的背景下阐明LN在抑制上皮层-介质细胞过渡 (EMT) 中的作用.
主要方法:
- 在大鼠皮磨损模型中诱导PAA,然后给予LN和氨酸 (HA).
- 使用酶相关的免疫吸收测试 (ELISA),伤口愈合测试,si-RNA和西斑分析来验证机制.
- 在体外实验中证实了TGF-β1/FOXC2通路的抑制.
主要成果:
- 在老鼠中,LN的使用显著改善了粘附.
- 线治疗降低了炎症性细胞因子 (TNF-α,IL-1β,IL-8) 和纤维化标志物的水平.
- 在实验室中,LN降低了TGF-β1和EMT标记物 (纤维素,E-cadherin) 的表达,并抑制了TGF-β1 / FOXC2通路.
结论:
- 利古斯特拉纳米颗粒 (LN) 通过减少炎症,降低EMT,并促进腹介质细胞修复来抑制PAA形成.
- LN显示出作为PAA治疗剂的潜力.
- 需要进一步的临床研究来证实LN在PAA治疗中的有效性.
相关概念视频
01:21Drugs for Treatment of Constipation-Predominant IBS
136
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
136
01:17Drugs for Treatment of Diarrhea-Predominant IBS
147
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
147
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
174
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
174
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
212
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
212